Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Lonza said it now expects its contract-drug-manufacturing, or CDMO, sales to grow by between 20% and 21% excluding currency movements for the full year, with a core earnings before interest, taxes, ...

Curiosity, stress and peer influence are among the main reasons why young Malaysians get involved in substance abuse, says ...

Health care companies recouped some of their recent losses amid generally strong earnings and deal activity. British drug maker AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, ...